Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis

  • Martínez García de la Torre, Raquel A.
  • Vallverdú, Julia
  • Xu, Zhenqing
  • Ariño, Silvia
  • Ferrer-Lorente, Raquel
  • Zanatto, Laura
  • Mercado-Gómez, Maria
  • Aguilar-Bravo, Beatriz
  • Ruiz-Blázquez, Paloma
  • Fernandez-Fernandez, Maria
  • Navarro-Gascon, Artur
  • Blasco-Roset, Albert
  • Sànchez-Fernàndez-de-Landa, Paula
  • Pera, Joan
  • Romero-Moya, Damia
  • Ayuso Garcia, Paula
  • Martínez Sánchez, Celia
  • Sererols Viñas, Laura
  • Cantallops Vilà, Paula
  • Cárcamo Giráldez, Carmen I.
  • McQuillin, Andrew
  • Morgan, Marsha Y.
  • Moya-Rull, Daniel
  • Montserrat, Núria
  • Eberlé, Delphine
  • Staels, Bart
  • Antoine, Bénédicte
  • Azkargorta, Mikel
  • Lozano, Juan-José
  • Martínez-Chantar, Maria L.
  • Giorgetti, Alessandra
  • Elortza, Félix
  • Planavila, Anna
  • Varela-Rey, Marta
  • Woodhoo, Ashwin
  • Zorzano, Antonio
  • Graupera, Isabel
  • Moles, Anna
  • Coll, Mar
  • Affo, Silvia
  • Sancho-Bru, Pau
Defining the trajectory of cells during differentiation and disease is key for uncovering the mechanisms driving cell fate and identity. However, trajectories of human cells remain largely unexplored due to the challenges of studying them with human samples. In this study, we investigate the proteome trajectory of iPSCs differentiation to hepatic stellate cells (diHSCs) and identify RORA as a key transcription factor governing the metabolic reprogramming of HSCs necessary for diHSCs' commitment, identity, and activation. Using RORA deficient iPSCs and pharmacologic interventions, we show that RORA is required for early differentiation and prevents diHSCs activation by reducing the high energetic state of the cells. While RORA knockout mice have enhanced fibrosis, RORA agonists rescue multi-organ fibrosis in in vivo models. Notably, RORA expression correlates negatively with liver fibrosis and HSCs activation markers in patients with liver disease. This study reveals that RORA regulates cell metabolic plasticity, important for mesoderm differentiation, pericyte quiescence, and fibrosis, influencing cell commitment and disease., P.S-B. is supported by Instituto de Salud Carlos III (ISCIII) “PI20/00765”, PI23/00724, “FORT23/00002”, “DTS22/00032”, AGAUR, “2021 PROD 00035”, 23-0356; Dissecting the role of the 14q32 region in hepatoblastoma “Hblast14” Worldwide Cancer Research; PRYCO223102ARME; Scientific Foundation of the Spanish Association Against Cancer (AECC); Q6922, (B-ORG) Plan Complementario de Biotecnología aplicada a la Salud del Plan de Recuperación, Transformación y Resiliencia. Ministerio de Ciencia e Innovación and co-founded the European research and innovation program Horizon HORIZON-HLTH−2022-STAYHLTH-02 under agreement no. 101095679. R.A M-G is funded by Instituto de Salud Carlos III “FI18/00215”, S.A. received a grant from the Ministerio de Educación, Cultura y Deporte “FPU17/04992”, C.M is funded by Centro de Investigación en Red Enfermedades Hepáticas y Digestivas (CIBERehd). A.G. is supported by Competitiveness (MINECO PID2020-15591RB-100), La Marató de TV3 (202001-32) and CERCA Programme/ Generalitat de Catalunya for institutional support. J.P. is supported by La Marató de TV3 (202001-32). D.R-M. is supported by Deutsche José Carreras Leukämie-Stiftung (DJCLS 13 R/2022). A.M. was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100; by MCIN/AEI/10.13039/501100011033 and El FSE invest in your future through the contract RYC 2016-19731; by Pfizer grant #77131383; P.R.B. was funded by Ministerio de Universidades fellowships FPU19/05357; M.F.F. was funded by FPU20/01367. M.V.-R. is supported by Proyecto PID2020-119486RB-100 (funded by MCIN/ AEI/10.13039/501100011033), Proyecto LABAECC2024 (funded by Asociación Española Contra el Cáncer, AECC), HORIZON-TMA-MSCA-Doctoral Networks 2021 (101073094), and Redes de Investigación 2022 (RED2022-134485-T). This study was funded by Instituto de Salud Carlos III through the Biobanks and Biomodels Platform and co‐funded by the European Union (PTC20/00013, PT20/00130, PT23/00009 and PTC23/00002 to N.M.) and by Instituto de Salud Carlos III and European Union—Next Generation EU, Plan de Recuperación Transformación y Resiliencia (TERAV/ISCIII RD21/0017/0018) to N.M; M.C. was funded by Ramon y Cajal programme from the Ministerio de Ciencia e Innovación RYC2019-026662-I. S.A. is funded by la Caixa Foundation “100010434” and the European Union’s Horizon 2020 under the Marie Skłodowska-Curie “847648”, PID2021-124694OA-I00, MCIN/AEI/ 10.13039/501100011033 and FEDER Una manera de hacer Europa, The European Union grant agreement 101077312*. Ramon y Cajal program RYC2022-036321-I. (* Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them”)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hepatic Stellate Cells Functional Heterogeneity in Liver Cancer

  • Sererols-Viñas, Laura
  • Garcia-Vicién, Gemma
  • Ruiz-Blázquez, Paloma
  • Lee, Ting-Fang
  • Lee, Youngmin A.
  • Gonzalez-Sanchez, Ester
  • Vaquero, Javier
  • Moles, Anna
  • Filliol, Aveline
  • Affò, Silvia
Hepatic stellate cells (HSCs) are the liver's pericytes, and play key roles in liver homeostasis, regeneration, fibrosis, and cancer. Upon injury, HSCs activate and are the main origin of myofibroblasts and cancer-associated fibroblasts (CAFs) in liver fibrosis and cancer. Primary liver cancer has a grim prognosis, ranking as the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) being the predominant type, followed by intrahepatic cholangiocarcinoma (iCCA). Moreover, the liver hosts 35% of all metastatic lesions. The distinct spatial distribution and functional roles of HSCs across these malignancies represent a significant challenge for universal therapeutic strategies, requiring a nuanced and tailored understanding of their contributions. This review examines the heterogeneous roles of HSCs in liver cancer, focusing on their spatial localization, dynamic interactions within the tumor microenvironment (TME), and emerging therapeutic opportunities, including strategies to modulate their activity, and harness their potential as targets for antifibrotic and antitumor interventions., S.A. is funded by the RYC2022-036321-I, MCIN/AEI/10.13039/501100011033/FEDER, Project PID2021-124694OA-I00, and The European Union grant agreement 101077312*. This work was also funded, in part, through the NIH/NCI Cancer Center Support Core Grant P30 CA008748 to A.A.F.; Y.A.L. is supported by 1R01DK133512 RSG-22-061-01-MM; A.M. is funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grant PID2021-123652OB-I00 and Pfizer grant #77131383; P.R.B. is funded by Ministerio de Universidades fellowships FPU19/05357. J.V. is funded by AEI, MICIN, through the project grant PID2022-141984OB-I00 and the “Ramon y Cajal” program RYC2021-034121-I.Figures Created in BioRender.*Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease

  • Ariño, Silvia
  • Ferrer-Lorente, Raquel
  • Serrano, Guillermo
  • Zanatto, Laura
  • Martínez-García de la Torre, Raquel A.
  • Gratacós-Ginès, Jordi
  • Rubio, Ana Belén
  • Pérez, Martina
  • Mateos-Sánchez, Carlos
  • Aguilar-Bravo, Beatriz
  • Atkinson, Stephen
  • Xu, Zhengqing
  • Cantallops-Vilà, Paula
  • Sererols-Viñas, Laura
  • Ruiz-Blázquez, Paloma
  • Rill, Aina
  • Fundora, Yiliam
  • Lozano, Juan José
  • Coll, Mar
  • Ochoa, Idoia
  • Affo, Silvia
  • Moles, Anna
  • Mereu, Elisabetta
  • Bataller, Ramón
  • Pose, Elisa
  • Sancho-Bru, Pau
Animal models poorly recapitulate advanced alcohol-associated liver disease (ALD), precluding the development of new treatments. Organoids have emerged as a powerful human-based preclinical tool; however, current patient-derived liver organoids fail to capture epithelial heterogeneity and require surgical resections, limiting their use in personalized disease modeling. Here, we describe the development of organoids from liver needle biopsies (b-Orgs) obtained from patients with ALD., This work has been supported by grants to P.S-B. Proyecto PI20/00765 and PI23/00724, funded by “Instituto de Salud Carlos III (ISCIII) co-financed by the European Union. By HORIZON-HLTH-2022- STAYHLTH-02, grant number 101095679, funded by the European Union. Project FORT23/00002, funded by Instituto de Salud Carlos III (ISCIII) "Programa FORTALECE del Ministerio de Ciencia, Innovación y Universidades". This work has also been co-financed for P.S-B by the Spanish Ministry of Science and Innovation with funds from the European Union NextGenerationEU, from the Recovery, Transformation and Resilience Plan (PRTR-C17.I1) and from the Autonomous Community of Catalonia within the framework of the Biotechnology Plan Applied to Health (Q6922). S.A. received a fellowship from the Ministerio de Educación, Cultura y Deporte (FPU17/04992). R.A. M-G. was funded by the Instituto de Salud Carlos III, PFIS (FI18/00215). B.A-B. was funded by Instituto de Salud Carlos III, PFIS (FI16/00203). M.C. is funded by the Ramon y Cajal program from the Ministerio de Ciencia e Innovación RYC2019-026662-I and by the State Plan of Scientific and Technical Research and Innovation PID2021-125195OB-I00. S.A. is funded by the MCIN/AEI/10.13039/501100011033 by “ERDF A way of making Europe” (PID2021-124694OA-I00) and the European Union grant agreement 101077312. A.M. was funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grants PID2021-123652OB-I00 and RTI2018-097475-A-100; by MCIN/AEI/10.13039/501100011033; by Pfizer grant #77131383; and the contract RYC-2016-19731. P.R-B received a fellowship from the Spanish Ministry of Education, Culture and Sports, FPU program (FPU19/05357)., Peer reviewed